A malignant sea snail poison can change diabetes care and improve the quality of life for those suffering from diabetes, reports a new study. Nearly one hundred years after the discovery of insulin, an international research team has developed the smallest fully functional hormone version of a cone snail.
Mini-Insulin– The new version of insulin has the potential for human insulin in addition to the potential for rapid action of the insulin toxin produced by predatory cone snails.
“We now have the ability to make hybrid versions of insulin that work in humans and which also seem to have many positive attributes of cone snail insulin. That is an important step forward in our efforts to make diabetes care safer and more effective, “Danny Hung-Chieh Chou, Ph.D., assistant professor of biochemistry at the University of Utah Health and one of the authors of the relevant study told Phys.Org.
Key properties of Mini-Insulin:
- Have similar in-vitro insulin signaling and in-vivo bioactivity similar to human insulin
- It works faster than human insulin, which works the fastest
- Rapid acting insulin will reduce the risk of hyperglycemia and other diabetes complications
- This new insulin can also improve the performance of insulin pumps or artificial pancreas that release insulin into the body whenever needed
- This can help individuals with diabetes to control their blood sugar levels more tightly and quickly
The research team found that new insulin derived from cone snail venom does not have a hinge compound that causes the human insulin hormone to clot so it can be stored in the pancreas. This aggregate must be simplified into individual molecules before they can start working on blood sugar.
They use structural biology and chemical drug techniques to isolate amino acids that help insulin slug bind to insulin receptors. The truncated version of the human insulin molecule is then made without the area that causes clots.
In testing in animals, new insulin insulin is bound to insulin receptors as strong as normal human insulin.
“Mini-insulin has tremendous potential. With only a few strategic changes, we have produced a strong and fast-acting molecular structure, which is the smallest and most fully active insulin to date. Because it is so small, it should be easy to synthesize, making it a prime candidate “for the development of a new generation of insulin therapy,” Chou told Phys.Org.
to request modification Contact us at Here or [email protected]